Experimental CLL drug cirmtuzumab tested for safety in retreatment

NCT ID NCT02860676

Completed Disease control Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested the safety of cirmtuzumab, an experimental antibody that targets a protein called ROR1 found on CLL cancer cells but rarely on healthy cells. Only 3 people with CLL who had previously received cirmtuzumab were retreated for 6 to 12 months. The main goal was to see if the drug is safe and tolerable, not whether it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cirmtuzumab (a monoclonal antibody that targets ROR1 on cancer cells)
What this could lead to: If it works, this could point toward a safer retreatment option for CLL that spares healthy cells.
What could go wrong: This is a very early, tiny study (only 3 people) focused on safety, not effectiveness. It may not work in humans or may have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA

Contacts and locations

Locations

UC San Diego Moores Cancer Center

La Jolla, California, 92093, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.